Alberto Margonato

Alberto Margonato

Auto-generated profile, based on publicly available information

Alberto Margonato

Faculty of Medicine and Surgery, Vita-Salute San Raffaele University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2010 in Journal of Cardiovascular Pharmacology and Therapeutics
Verified
Journal Article
Closed access
PDF file
MCMichela Cera
Michela Cera
ASAnna Salerno
Anna Salerno
GFGabriele Fragasso
Gabriele Fragasso
CMClaudia Montanaro
Claudia Montanaro
CGChiara Gardini
Chiara Gardini
AMAlberto Margonato
Alberto Margonato
The aim of the study was to assess whether trimetazidine (TMZ) could affect dispersion of atrial depolarization and ventricular repolarization. Corrected QT interval (QTc), QTc dispersion (QTc-d), Tpeak—Tend, and Tpeak—Tend dispersion (Tpeak—Tend-d) were measured in 30 patients with chronic heart failure (CHF) before and 6 months after randomization to conventional therapy plus TMZ (17 patients) or conventional therapy alone (13 patients). After 6 months, QTc was significantly reduced in both groups, whereas QT-peak was increased only in control group. Tpeak—Tend-d decreased (from 63.53 ± 24.73 to 42.35 ± 21.07 milliseconds, P = .006) only in TMZ group. When subgrouped according to CHF etiology, only ischemic patients on TMZ showed Tpeak—Tend-d reduction (65.00 ± 27.14 vs 36.67 ± 11.55 milliseconds, P = .001 in ischemic patients; 60.00 ± 20.00 vs 56.00 ± 33.86 milliseconds, P = NS, in nonischemic). These electrophysiological properties indicate an undiscovered mechanism of action of TMZ, which could be useful in conditions at risk of major arrhythmias.

13 May 2020 in European Heart Journal - Cardiovascular Pharmacotherapy
Verified
Journal Article
Closed access
PSPierre SABOURET
Pierre SABOURET
GGGiuseppe Galati
Giuseppe Galati
DADenis Angoulvant
Denis Angoulvant
OGOlga Germanova
Olga Germanova
Silvia CastellettiSilvia Castelletti
Silvia Castelletti
AMAlberto Margonato
Alberto Margonato
Type 2 diabetes mellitus (T2DM) portends high risk of atherosclerotic cardiovascular (CV) events and of CV mortality; moreover, this group of patients has a very high probability of developing heart failure (HF). In this review, we discuss new advances in pharmacological treatment both in CV prevention and in HF management with a special focus on T2DM patients. A large number of randomized clinical trials and meta-analyses provided strong evidence about therapeutic strategies acting on glucose metabolism, such as GLP-1 RA and SGLT2i and about lipid-lowering treatment, such as PCSK9i and icosapent ethyl. Moreover, SGLT2i demonstrated strong evidence of benefit particularly in HF management both in diabetic and non-diabetic patients. The pathophysiological bases of multiple mechanisms of benefit of this class of drug explain the unexpected and remarkable results demonstrated both by prevention trials and by trials dedicated only to HF (like DAPA-HF). These, new drugs in the CV therapeutic armamentarium are establishing a new comprehensive approach from prevention to therapy of HF, giving more emphasis on HF classification in four stages (A→D). New therapies, which are on the horizon, promise to further reduce CV mortality and morbidity in HF patients irrespective of diabetic status.

31 July 2007 in AIDS
Verified
Journal Article
Open access
NGNicola Gianotti
Nicola Gianotti
MGMonica Guffanti
Monica Guffanti
LGLaura Galli
Laura Galli
AMAlberto Margonato
Alberto Margonato
GCGiulia Chiaravalli
Giulia Chiaravalli
ACAntonella Castagna
Antonella Castagna
The QRS interval of 56 out of 75 (74.7%) HIV-infected, drug-experienced patients (66.7% men) increased during treatment with boosted or unboosted atazanavir by a median 5 ms (interquartile range 0–9; P < 0.0001); the PR and the QTc intervals did not change significantly. New asymptomatic bundle branch blocks were observed in four patients; one subject with a baseline first-degree atrioventricular block developed symptomatic bradyarrhythmia while receiving atenolol. The electrocardiographic monitoring of patients treated with atazanavir seems advisable.

29 April 2019 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
EMElisabetta Moscarella
Elisabetta Moscarella
AIAlfonso Ielasi
Alfonso Ielasi
ABAlessandro Beneduce
Alessandro Beneduce
GFGiuseppe Ferrante
Giuseppe Ferrante
CPCarlo Andrea Pivato
Carlo Andrea Pivato
CGCosmo Godino
Cosmo Godino


1 August 2020 in The American Journal of Cardiology
Verified
Journal Article
Closed access
CGCosmo Godino
Cosmo Godino
CPCarlo Andrea Pivato
Carlo Andrea Pivato
CRClaudia Rubino
Claudia Rubino
ARAnita Russi
Anita Russi
MCMichela Cera
Michela Cera
AMAlberto Margonato
Alberto Margonato